
XBIO Valuation
Xenetic Biosciences Inc
- Overview
- Forecast
- Valuation
- Earnings
XBIO Relative Valuation
XBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XBIO is overvalued; if below, it's undervalued.
Historical Valuation
Xenetic Biosciences Inc (XBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 1.98 is considered Fairly compared with the five-year average of -2.94. The fair price of Xenetic Biosciences Inc (XBIO) is between 3.02 to 5.20 according to relative valuation methord.
Relative Value
Fair Zone
3.02-5.20
Current Price:3.64
Fair
-1.20
PE
1Y
3Y
5Y
Trailing
Forward
-0.08
EV/EBITDA
Xenetic Biosciences Inc. (XBIO) has a current EV/EBITDA of -0.08. The 5-year average EV/EBITDA is 0.08. The thresholds are as follows: Strongly Undervalued below -2.03, Undervalued between -2.03 and -0.98, Fairly Valued between 1.13 and -0.98, Overvalued between 1.13 and 2.18, and Strongly Overvalued above 2.18. The current Forward EV/EBITDA of -0.08 falls within the Historic Trend Line -Fairly Valued range.
-0.08
EV/EBIT
Xenetic Biosciences Inc. (XBIO) has a current EV/EBIT of -0.08. The 5-year average EV/EBIT is 0.08. The thresholds are as follows: Strongly Undervalued below -2.02, Undervalued between -2.02 and -0.97, Fairly Valued between 1.13 and -0.97, Overvalued between 1.13 and 2.18, and Strongly Overvalued above 2.18. The current Forward EV/EBIT of -0.08 falls within the Historic Trend Line -Fairly Valued range.
1.98
PS
Xenetic Biosciences Inc. (XBIO) has a current PS of 1.98. The 5-year average PS is 9.14. The thresholds are as follows: Strongly Undervalued below -9.57, Undervalued between -9.57 and -0.22, Fairly Valued between 18.49 and -0.22, Overvalued between 18.49 and 27.85, and Strongly Overvalued above 27.85. The current Forward PS of 1.98 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Xenetic Biosciences Inc. (XBIO) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Xenetic Biosciences Inc. (XBIO) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.25. The thresholds are as follows: Strongly Undervalued below -1.40, Undervalued between -1.40 and -0.82, Fairly Valued between 0.33 and -0.82, Overvalued between 0.33 and 0.91, and Strongly Overvalued above 0.91. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Xenetic Biosciences Inc (XBIO) has a current Price-to-Book (P/B) ratio of 1.10. Compared to its 3-year average P/B ratio of 0.67 , the current P/B ratio is approximately 64.68% higher. Relative to its 5-year average P/B ratio of 0.90, the current P/B ratio is about 22.22% higher. Xenetic Biosciences Inc (XBIO) has a Forward Free Cash Flow (FCF) yield of approximately -47.87%. Compared to its 3-year average FCF yield of -63.95%, the current FCF yield is approximately -25.15% lower. Relative to its 5-year average FCF yield of -54.41% , the current FCF yield is about -12.02% lower.
1.10
P/B
Median3y
0.67
Median5y
0.90
-47.87
FCF Yield
Median3y
-63.95
Median5y
-54.41
Competitors Valuation Multiple
The average P/S ratio for XBIO's competitors is 0.50, providing a benchmark for relative valuation. Xenetic Biosciences Inc Corp (XBIO) exhibits a P/S ratio of 1.98, which is 297.58% above the industry average. Given its robust revenue growth of 16.14%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of XBIO decreased by 17.25% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 510.82K to 593.26K.
The secondary factor is the P/E Change, contributed 1.54%to the performance.
Overall, the performance of XBIO in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch

XHG
XChange TEC.INC
1.370
USD
-0.72%

UBXG
U-BX Technology Ltd
3.290
USD
+10.40%

BLBX
Blackboxstocks Inc
7.550
USD
0.00%

EVOK
Evoke Pharma Inc
3.950
USD
0.00%

CREG
Smart Powerr Corp
1.900
USD
0.00%

IMG
CIMG Inc
0.243
USD
0.00%

ONFO
Onfolio Holdings Inc
1.140
USD
0.00%

GRI
GRI Bio Inc
1.960
USD
0.00%

PLRZ
Polyrizon Ltd
1.460
USD
0.00%

CMND
Clearmind Medicine Inc
0.989
USD
0.00%
FAQ

Is Xenetic Biosciences Inc (XBIO) currently overvalued or undervalued?
Xenetic Biosciences Inc (XBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 1.98 is considered Fairly compared with the five-year average of -2.94. The fair price of Xenetic Biosciences Inc (XBIO) is between 3.02 to 5.20 according to relative valuation methord.

What is Xenetic Biosciences Inc (XBIO) fair value?

How does XBIO's valuation metrics compare to the industry average?

What is the current P/B ratio for Xenetic Biosciences Inc (XBIO) as of Jul 30 2025?

What is the current FCF Yield for Xenetic Biosciences Inc (XBIO) as of Jul 30 2025?

What is the current Forward P/E ratio for Xenetic Biosciences Inc (XBIO) as of Jul 30 2025?
